Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yuichiro Honma"'
Autor:
Misa Ogiwara, Hiroaki Ihara, Manami Haba, Hiroki Nakazawa, Saori Hotta, Hitomi Jo, Noriko Hayama, Yuichiro Honma, Sakuo Hoshi, Mitsuhiro Fujii, Kazuhisa Takahashi
The coronavirus disease 2019 (COVID-19) is a condition caused by the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) which first emerged in December 2019. Although several papers have reported the presence bradycardia in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5adfd62f27bf9b49e36d94176f6380e
https://doi.org/10.21203/rs.3.rs-1817182/v1
https://doi.org/10.21203/rs.3.rs-1817182/v1
Autor:
Yuichiro Honma1,2, Shinsaku Togo1,2 shinsaku@juntendo.ac.jp, Kazue Shimizu1,2, Miniwan Tulafu1,2, Takuo Hayashi3, Toshimasa Uekusa4, Shigeru Tominaga5, Kenji Kido6, Yuichi Fujimoto1,2, Yukiko Nanba1,2, Kazuya Takamochi7, Shiaki Oh7, Kenji Suzuki7, Kazuhisa Takahashi1,2
Publikováno v:
Oncology Letters. Sep2017, Vol. 14 Issue 3, p3319-3326. 8p.
Autor:
Kazue Shimizu, Yuichi Fujimoto, Yukiko Nanba, Yuichiro Honma, Shigeru Tominaga, Kenji Suzuki, Kenji Kido, Toshimasa Uekusa, Miniwan Tulafu, Takuo Hayashi, Kazuhisa Takahashi, Shinsaku Togo, Kazuya Takamochi, Shiaki Oh
Publikováno v:
Oncology Letters
Non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SCC) histology have limited chemotherapeutic options. Treatment with S-1 combined with carboplatin (CBDCA) has been shown to provide a significant survival benefit in SCC patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac27cb374236b6e1db9e4a9c51af91e5
https://doi.org/10.3892/ol.2017.6610
https://doi.org/10.3892/ol.2017.6610
Autor:
Naoko Shimada, Takehito Shukuya, Fumiyuki Takahashi, Kazuhisa Takahashi, Tetsuhiko Asao, Motoyasu Kato, Keiko Muraki, Rina Shibayama, Ryo Koyama, Shoko Sakuraba, Kentaro Suina, Yuichiro Honma
Publikováno v:
Cancer Treatment and Research Communications. 9:106-110
Background Chemotherapy is a standard treatment for patients with advanced non-small cell lung cancer (NSCLC); however, it occasionally causes adverse events. Serious adverse events (SAEs) are defined as any untoward medical occurrence that is relate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f1df57b9a6b4d6b564416a4a211a640
https://doi.org/10.1016/j.ctarc.2016.09.001
https://doi.org/10.1016/j.ctarc.2016.09.001
Autor:
Yuta Nanjo, Naoko Shimada, Kazuhisa Takahashi, Keiko Muraki, Fumiyuki Takahashi, Yuichiro Honma, Ryo Koyama, Rina Shibayama, Keita Mori, Takehito Shukuya, Motoyasu Kato, Ryota Kanemaru
Publikováno v:
BMC Cancer
Background Advanced non-small cell lung cancer (NSCLC) patients often develop thromboembolic events, including cerebral infarction (CI). However, the relationship between advanced NSCLC and CI has not been thoroughly investigated. We examined the ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2002550d5ba8197421dcf08b992998a
http://europepmc.org/articles/PMC4785661
http://europepmc.org/articles/PMC4785661
Autor:
Keita Mori, Naoko Shimada, Takehito Shukuya, Ryo Ko, Ryo Koyama, Yuichiro Honma, Ryota Kanemaru, Kazuhisa Takahashi, Shigehiro Yagishita, Motoyasu Kato, Rina Shibayama
Publikováno v:
Cancer chemotherapy and pharmacology. 76(4)
Docetaxel or pemetrexed monotherapy is recommended either as a second-line treatment for non-small cell lung cancer (NSCLC) patients without EGFR mutation or ALK fusion genes or as a third-line treatment for patients with EGFR mutation or ALK fusion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10801aacc56408cd6fb11a2708c5fc99
https://pubmed.ncbi.nlm.nih.gov/26259641
https://pubmed.ncbi.nlm.nih.gov/26259641
Autor:
Kazuya Takamochi, Naoko Shimada, Yuichiro Honma, Rina Shibayama, Ryo Koyama, Kazuhisa Takahashi, Shiaki Oh, Ryota Kanemaru, Takehito Shukuya, Kenji Suzuki
Publikováno v:
Journal of Clinical Oncology. 32:e18527-e18527
e18527 Background: As the efficacy of chemotherapy for advanced lung cancer patients has been increased, some advanced lung cancer patients may benefit from combined modality therapy including surg...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d96fb7db2dd9dddc044af93360562caf
https://doi.org/10.1200/jco.2014.32.15_suppl.e18527
https://doi.org/10.1200/jco.2014.32.15_suppl.e18527
Autor:
Keiko Muraki, Shoko Sakuraba, Takehito Shukuya, Kazuhisa Takahashi, Naoko Shimada, Kentaro Suina, Motoyasu Kato, Rina Shibayama, Ryo Koyama, Yuichiro Honma, Tetsuhiko Asao
Publikováno v:
Journal of Clinical Oncology. 32:e19129-e19129
e19129 Background: Serious adverse events, which cause immediate hospitalization, prolonged hospitalization, permanent damage, or death, are clinically defined as severe adverse events (SAEs). Few ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::272921923f4e7df2df34edb41598edef
https://doi.org/10.1200/jco.2014.32.15_suppl.e19129
https://doi.org/10.1200/jco.2014.32.15_suppl.e19129
Autor:
Motoyasu Kato, Takehito Shukuya, Keita Mori, Ryota Kanemaru, Yuichiro Honma, Yuta Nanjo, Keiko Muraki, Rina Shibayama, Ryo Koyama, Naoko Shimada, Fumiyuki Takahashi, Kazuhisa Takahashi, Kato, Motoyasu, Shukuya, Takehito, Mori, Keita, Kanemaru, Ryota, Honma, Yuichiro, Nanjo, Yuta, Muraki, Keiko, Shibayama, Rina
Publikováno v:
BMC Cancer; 3/10/2016, Vol. 16, p1-7, 7p, 1 Diagram, 5 Charts, 2 Graphs
Autor:
Naoko Shimada, Kazuhisa Takahashi, Ryo Koyama, Kentaro Suina, Takehito Shukuya, Tetsuhiko Asao, Rina Ohashi, Shoko Sakuraba, Keiko Muraki, Yuichiro Honma
Publikováno v:
Annals of Oncology. 24:ix94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20ba3f51c1f9bd0c009874b8a105b583
https://doi.org/10.1093/annonc/mdt460.141
https://doi.org/10.1093/annonc/mdt460.141